Comparative Pharmacology
Head-to-head clinical analysis: BLUDIGO versus EVANS BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLUDIGO versus EVANS BLUE.
BLUDIGO vs EVANS BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
Evans Blue is a diazo dye that binds reversibly to plasma proteins, primarily albumin. Its primary utility is as a visual indicator for the estimation of blood volume or plasma volume via dye dilution technique. It also has histological applications for staining myelin sheaths and detecting blood-brain barrier disruption.
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
Adults: 0.5-1.0 mL of 0.5% solution (2.5-5 mg) IV bolus for determination of blood volume. Repeat doses must be separated by at least 1 hour due to slow clearance.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life ranges from 2 to 12 hours, mean approximately 6 hours; prolonged in hepatic impairment or decreased albumin levels.
Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%.
Primarily excreted unchanged in bile (80-90%) into feces; renal elimination accounts for <5% due to high protein binding.
Category C
Category C
Diagnostic Dye
Diagnostic Dye